Circulating regulatory T cells (CD4+CD25+FOXP3+) decrease in breast cancer patients after vaccination with a modified MHC class II HER2/neu (AE37) peptide

Jeremy D. Gates, Guy T. Clifton, Linda C. Benavides, Alan K. Sears, Mark G. Carmichael, Matthew Timothy Hueman, Jarrod P. Holmes, Yusuf H. Jama, Mohamed Mursal, Athina Zacharia, Kathy Ciano, Steven Khoo, Alexander Stojadinovic, Sathibalan Ponniah, George E. Peoples

Research output: Contribution to journalArticle


Regulatory T cells (TReg), CD4+CD25+FOXP3+, are implicated in suppressing tumor immune responses. We analyzed peripheral blood lymphocytes (PBL) from breast cancer patients receiving a modified HLA class II HER2/neu peptide (AE37) vaccine for TReg cells and correlated their levels with vaccine-specific immune responses. The mean CD4+CD25+FOXP3+ TReg cells decreased in patients with vaccination with no significant difference in serum TGF-β levels. IFN-γ ELISPOT and DTH increased after vaccination with a good correlation between TReg cell reduction and size of DTH to AE37. The TReg cell reduction and associated immune response suggest that AE37 may be clinically useful.

Original languageEnglish (US)
Pages (from-to)7476-7482
Number of pages7
Issue number47
Publication statusPublished - Nov 3 2010
Externally publishedYes



  • HER2/neu
  • Regulatory T cell
  • Vaccine

ASJC Scopus subject areas

  • Immunology and Microbiology(all)
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)
  • Molecular Medicine

Cite this